相似文献
1
Possible Benefit and Validity of Supplements for Alcohol Use Disorder.
Alcohol Clin Exp Res. 2019 May;43(5):780-782. doi: 10.1111/acer.13990. Epub 2019 Mar 14.
2
Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.
Alcohol Clin Exp Res. 2020 Jan;44(1):23-35. doi: 10.1111/acer.14233. Epub 2019 Dec 5.
3
Biopharmaceutical Drug Development Pillars: Begin With the End in Mind.
Clin Pharmacol Ther. 2019 Jan;105(1):33-35. doi: 10.1002/cpt.1273. Epub 2018 Dec 2.
4
Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder.
Alcohol Clin Exp Res. 2018 Sep;42(9):1612-1622. doi: 10.1111/acer.13829. Epub 2018 Jul 30.
5
The FNIH Biomarkers Consortium embraces the BEST.
Nat Rev Drug Discov. 2019 Jul;18(8):567-568. doi: 10.1038/d41573-019-00015-w.
6
Decision-making in drug development using a composite definition of success.
Pharm Stat. 2018 Sep;17(5):555-569. doi: 10.1002/pst.1870. Epub 2018 Jun 28.
7
Choosing drugs for UK COVID-19 treatment trials.
Nat Rev Drug Discov. 2022 Feb;21(2):81-82. doi: 10.1038/d41573-021-00203-7.
8
Bayesian joint modelling of benefit and risk in drug development.
Pharm Stat. 2018 May;17(3):248-263. doi: 10.1002/pst.1852. Epub 2018 Feb 22.
9
Innovative Trial Designs in GI Drug Development: Why Trials Succeed and Fail-A Brief Report From 2018 Digestive Disease Week.
Gastroenterology. 2019 Apr;156(5):1239-1242. doi: 10.1053/j.gastro.2019.01.001. Epub 2019 Jan 6.
10
[Pharmacological research and pluripotent stem cells: from the innovative experimental paradigm to the successful clinical trial].
Med Sci (Paris). 2019 Jan;35(1):26-29. doi: 10.1051/medsci/2018316. Epub 2019 Jan 23.
引用本文的文献
1
Citicoline: pharmacological and clinical review, 2022 update.
Rev Neurol. 2022 Nov 30;75(s05):S1-S89. doi: 10.33588/rn.75s05.2022311.
本文引用的文献
1
A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder.
Alcohol Clin Exp Res. 2019 Feb;43(2):317-323. doi: 10.1111/acer.13928. Epub 2018 Dec 24.
2
Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects.
Sci Rep. 2017 May 31;7(1):2496. doi: 10.1038/s41598-017-02442-4.
3
Repurposing Tigecycline for the Treatment of Alcohol Use Disorder.
Alcohol Clin Exp Res. 2017 Mar;41(3):497-500. doi: 10.1111/acer.13312. Epub 2017 Jan 30.
4
The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives.
Clin Interv Aging. 2015 Sep 3;10:1421-9. doi: 10.2147/CIA.S87886. eCollection 2015.
5
Citicoline in addictive disorders: a review of the literature.
Am J Drug Alcohol Abuse. 2014 Jul;40(4):262-8. doi: 10.3109/00952990.2014.925467. Epub 2014 Jun 20.
6
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
JAMA. 2014 May 14;311(18):1889-900. doi: 10.1001/jama.2014.3628.
7
Targeted opioid receptor antagonists in the treatment of alcohol use disorders.
CNS Drugs. 2013 Oct;27(10):777-87. doi: 10.1007/s40263-013-0096-4.
8
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Addiction. 2013 Feb;108(2):275-93. doi: 10.1111/j.1360-0443.2012.04054.x. Epub 2012 Oct 17.
9
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).
Lancet. 2012 Jul 28;380(9839):349-57. doi: 10.1016/S0140-6736(12)60813-7. Epub 2012 Jun 11.
10
Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers.
J Addict Med. 2011 Mar;5(1):57-64. doi: 10.1097/ADM.0b013e3181d80c93.
Zotero 插件